An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis

Trial Profile

An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Secukinumab (Primary) ; Secukinumab (Primary) ; Corticosteroids
  • Indications Anterior uveitis; Behcet's syndrome; Immune-mediated uveitis; Intermediate uveitis; Panuveitis; Posterior uveitis; Sarcoidosis
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Nov 2012 Planned end date changed from 1 Sep 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 21 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top